Business
ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing Deal
SILICON VALLEY, CA - August 22, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematolog...
About this update from Abvc Biopharma, Inc.
[{"type":"image","caption":"","headline":"ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States","size":{"original":{"width":140,"height":78,"url":"https://media.zenfs.com/en/newsmediawire_165/abacbb2aeeae890aef297a130fea97c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X_qKvHxujBtXyrHhszohog--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNztjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/abacbb2aeeae890aef297a130fea97c7","width":140,"height":78}}},{"type":"text","content":"SILICON VALLEY, CA - August 22, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today announced that it has received an additional $100,000 licensing payment from ForSeeCon Eye Corporation ("ForSeeCon") under the global licensing agreement covering the Company's innovative vitreous substitute, Vitargus(R).","length":504,"tagName":"p"},{"type":"text","content":"Strong Financial Impact","length":23,"tagName":"p"},{"type":"text","content":"With this latest payment, ABVC has now collected a cumulative $495,000 in cash licensing payments from ForSeeCon.","length":113,"tagName":"p"},{"type":"text","content":"The overall licensing structure includes:","length":41,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"$30 million already delivered in equity consideration, represented by 5 million ForSeeCon shares based on an internal equity valuation.","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"$3.5 million in total cash licensing payments, of which $495,000 has been received to date.","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"Up to $60 million in sales royalties (5% of net sales), payable if Vitargus(R) reaches commercialization.","length":105,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":331,"olType":false},{"type":"text","content":"This blended structure of equity, milestone cash, and royalties underscores both the near-term liquidity and long-term upside potential embedded in the ForSeeCon collaboration.","length":176,"tagName":"p"},{"type":"text","content":"Licensing Payment and Equity Summary","length":36,"tagName":"p"}...